Ocugen studies: COVAXIN potentially effective against three key variants of SARS-CoV-2

 

• COVAXIN effectively neutralizes Brazil variant along with UK variant and India double mutant variant
  
  

• Potential effectiveness against multiple variants reduces the possibility of mutant virus escape
  
  

• According to World Health Organization, the double mutant variant of SARS-CoV-2 has spread to at least 17 countries
  

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that in a new study, scientists at Indian Council of Medical Research (ICMR)-National Institute of Virology have found that COVAXIN demonstrated potential effectiveness against the Brazil variant of SARS-CoV-2, B.1.128.2. As previously disclosed, a study conducted by ICMR also suggested that COVAXIN was effective against the UK variant, B.1.1.7, as well as the Indian double mutant variant, B.1.617. It is notable that the Brazilian variant, B1.128.2, contains the E484K mutation that was found in New York.

In the ICMR studies, COVAXIN-vaccinated sera effectively neutralized several SARS-CoV-2 variants (B.1.617 (India, double mutant), B.1.1.7 (United Kingdom), B.1.1.28 (Brazil P2), and heterologous strain) in an in-vitro plaque reduction neutralization assay. These studies suggest that COVAXIN vaccination may be effective against multiple SARS-CoV-2 variants.

https://finance.yahoo.com/news/ocugen-announces-studies-showing-covaxin-113000104.html